YM-201627: An orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation

Cancer Letters

Volumn 238, Issue 1, 2006, Pages 119-127

  Amino, Nobuaki ^a   Ideyama, Yukitaka ^a   Yamano, Mayumi ^a   Kuromitsu, Sadao ^a   Tajinda, Katsunori ^a   Samizu, Kiyohiro ^a   Matsuhisa, Akira ^a   Kudoh, Masafumi ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Angiogenesis; Endothelial cells; Vascular endothelial growth factor (VEGF); YM 201627

Indexed keywords

ANTINEOPLASTIC AGENT; MATRIGEL; UNCLASSIFIED DRUG; YM 201627;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL LINE; CELL PROLIFERATION; CELL STIMULATION; CELL TYPE; CONTROLLED STUDY; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; VASCULAR ENDOTHELIUM; XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; PHOSPHORYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744946282     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.037     Document Type: Article

References (31)

1. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
2. Ishigami S., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 78 (1998) 1379-1384
3. Bussolino F., Mantovani A., and Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 22 (1997) 251-256
4. Folkman J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 235 (1995) 1757-1763
5. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
6. Salven P., Heikkila P., and Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer 76 (1997) 930-934
7. Shibusa T., Shijubo N., and Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin. Cancer Res. 4 (1998) 1483-1487
8. Okita S., Kondoh S., Shiraishi K., Kaino S., Hatano S., and Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer clinical studies. Int. J. Oncol. 12 (1998) 1013-1018
9. Abdulrauf S.I., Edvardsen K., Ho K.L., Yang X.Y., Rock J.P., and Rosenblum M.L. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J. Neurosurg. 88 (1998) 513-520
10. Eppenberger U., Kueng W., Schlaeppi J.-M., Roesel J.L., Benz C., Mueller H., et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 16 (1998) 3129-3136
11. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
12. Pepper M.S., Ferrara N., Orci L., and Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189 (1992) 824-831
13. Pepper M.S., Ferrara N., Orci L., and Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181 (1991) 902-906
14. Unemori E.N., Ferrari N., Bauer E.A., and Amento E.P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol. 153 (1992) 557-562
15. Lamoreaux W.J., Fitzgerald M.E., Reiner A., Hasty K.A., and Charles S.T. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc. Res. 55 (1998) 29-42
16. Zondor S.D., and Medina P.J. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. 38 (2004) 1258-1264
17. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59 (1999) 99-106
18. Mathis G. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41 (1995) 1391-1397
19. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67 (1992) 519-528
20. Nakatsu M.N., Sainson R.C., Aoto J.N., Taylor K.L., Aitkenhead M., Perez-del-Pulgar S., et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc. Res. 66 (2003) 102-112
21. Eskens F.A. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Brit. J. Cancer 90 (2004) 1-7
22. Marzola P., Degrassi A., Calderan L., Farace P., Crescimanno C., Nicolato E., et al. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin. Cancer Res. 10 (2004) 739-750
23. Stopeck A., Sheldon M., Vahedian M., Cropp G., Gosalia R., and Hannah A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 8 (2003) 2798-2805
24. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
25. Goldbrunner R.H., Bendszus M., Wood J., Kiderlen M., Sasaki M., and Tonn J.C. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55 (2004) 426-432
26. Ciardiello F., Bianco R., Caputo R., Caputo R., Damiano V., Troiani T., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy, Clin. Cancer Res. 10 (2004) 784-793
27. Beebe J.S., Jani J.P., Knauth E., Goodwin P., Higdon C., Rossi A.M., et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy, Cancer Res. 63 (2003) 7301-7309
28. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348 (1990) 555-557
29. Kumeda S.I., Deguchi A., Toi M., Omura S., and Umezawa K. Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res. 19 (1999) 3961-3968
30. Ohno O., Shima Y., Ikeda Y., Kondo S.I., Kato K., Toi M., et al. Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. Int. J. Oncol. 18 (2001) 1009-1015
31. Ho P.Y., Liang Y.C., Ho Y.S., Chen C.T., and Lee W.S. Inhibition of human vascular endothelial cells proliferation by terbinafine. Int. J. Cancer 111 (2004) 51-59